ELAVL1 and cancer: As Fig 2 showed that patients with higher expression of HuR displayed poorer OS across pan-cancer, including ACC (p < 0.0001), BRCA (p = 0.031), GBM-LGG (p < 0.0001), KICH (p = 0.07), LGG (p < 0.0001), LIHC (p = 0.003), LUAD (p = 0.00028), MESO (p = 0.0012), PAAD (p = 0.016), SARC (p = 0.0068), SKCM (p = 0.022), and UVM (p = 0.055).